This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Topiramate Linked to Infants' Risk for Oral Birth Defects
FDA Adds New Warnings to Drug for Epilepsy, Migraines
By News Staff
"The benefits and the risks of topiramate should be carefully weighed when prescribing this drug to women of childbearing age, particularly for conditions not usually associated with permanent injury or death," Shepherd said. "Alternative medications that have a lower risk of oral clefts and other adverse birth outcomes should be considered for these patients.
"If the decision is made to use topiramate in women of childbearing age, effective birth control should be used."
In a March 4 safety announcement, the FDA said physicians also should be aware of the potential for a decrease in hormonal exposure and a possible decrease in contraceptive efficacy in patients who use estrogen-containing birth control while taking topiramate.
Topiramate is approved to treat patients with epilepsy and to prevent migraine headaches. From 2007 through 2010, more than 32 million topiramate prescriptions were dispensed in the United States, and more than 4 million patients filled topiramate prescriptions at the nation's retail pharmacies, according to figures provided by the health care analytics firm SDI Health LLC.
Data from the North American Antiepileptic Drug, or NAAED, Pregnancy Registry show that the prevalence of oral clefts in infants exposed to topiramate monotherapy during the first trimester of pregnancy was 1.4 percent, compared with a prevalence of 0.38 percent to 0.55 percent in infants exposed to other antiepileptic drugs during the same period. Infants of mothers without epilepsy or treatment with other antiepileptic drugs had a prevalence of 0.07 percent.
The agency said in its safety announcement that the patient medication guide and prescribing information for topiramate will be updated to reflect the new safety data.
The FDA also said that topiramate is being reclassified as a pregnancy category D drug, meaning there is positive evidence of fetal risk based on human data, but the potential benefits from use of the drug in pregnant women may be acceptable in certain situations despite its risks. The drug had been classified as a pregnancy category C drug because at the time of its approval, data from animal studies suggested potential fetal risks but data from human clinical trials or studies were inadequate or unavailable.
In addition to the recommendations Shepherd made, the FDA offered the following recommendations for health care professionals:
- inform patients of the NAAED Pregnancy Registry and encourage patients who become pregnant while taking topiramate to enroll by calling (888) 233-2334; and
- report adverse events involving topiramate to the FDA's MedWatch program.
Risk to Newborns Leads FDA To Require New Labels for All Antipsychotic Drugs
Medications Pose Risks During Pregnancy
Terbutaline Poses Severe Risks to Pregnant Women, Says FDA
Boxed Warning, Contraindication to Be Added to Asthma Drug's Label
More From AAFP
American Family Physician: "Excerpt on Epilepsy from the Clinical Evidence Handbook"
FDA: Topiramate (marketed as Topamax) Information